Skip to main content
SpringerLink
Log in

Innovative Approach to Treatment of the Metabolic Syndrome

  • Chapter
Principles of Metabolic Surgery

  • 1168 Accesses

Abstract

In recent decades, we have seen a massive increase in the incidence of the metabolic syndrome. With the advent of bariatric surgery as the most effective method to achieve and maintain weight loss, multiple changes have also been discovered regarding its role in the management of diabetes and the metabolic syndrome. There is now extensive evidence to support metabolic surgery as a treatment not only for obesity but also for the well documented metabolic derangements that accompany it. The site of nutrient delivery in the gastrointestinal tract, malabsorption, and gut hormone secretion are all believed to play important roles in the proposed mechanism of action of metabolic surgery. Although the mechanisms of the longterm remission of diabetes and other obesity-associated co-morbidites are still being outlined, novel techniques and surgical innovations have provided very promising results in select groups of patients. This chapter deals with the history of metabolic surgery and its effects on diabetes and the metabolic syndrome. An overview of several hypotheses and theories behind the surgically induced changes that may lead to sustained remission of this disease is given, along with a discussion of the ongoing trials, to create a better understanding of the future role of surgery in the management of this patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Flegal, KM, Caroll MD, Ogden CL et al (2002) Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288:1723–1727

    Article  PubMed  Google Scholar 

  2. Ford ES (2005) Risks for all cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:769–1778

    Google Scholar 

  3. Brown SA, Upchwich S, Anding R et al (1996) Promoting weight loss in type II diabetes. Diabetes Care 19:613–624

    Article  PubMed  CAS  Google Scholar 

  4. Field AE, Coakley EH, Must A et al (2001) Impact of overweight on the risk of developing common chronic diseases during a 10- year period. Arch Intern Med 161:1581–1586

    Article  PubMed  CAS  Google Scholar 

  5. Zimet P, Shaw J, Alberti KG (2003) Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabetes Med 20:693–702

    Article  Google Scholar 

  6. Buchwald H, Avidor Y, Braumwald E, Jensen MD, Pories W, Fahrbach K et al (2004) Bariatric surgery: a systematic review and meta-analysis. JAMA 292:1724–1737

    Article  PubMed  CAS  Google Scholar 

  7. Pories WJ, Swanson MS, MacDonald KG et al (1995) Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:339–350

    Article  PubMed  CAS  Google Scholar 

  8. Schauer PR, Ikramuddin S, Gourash W et al (2000) Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 232:515–529

    Article  PubMed  CAS  Google Scholar 

  9. American Diabetes Association, The dangerous toll of diabetes. www.diabetes.org/diabetes-statistics/dangerous-toll.jsp

  10. American Diabetes Association, Diabetes Statistics. www.diabetes.org/diabetes-statistics/prevalence.jsp

  11. American Diabetes Association, Direct and indirect cost of diabetes in the United States. www.diabetes.org/diabetesstatistics/cost-of-diabetes-in-us.jsp

  12. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787

    Article  PubMed  CAS  Google Scholar 

  13. Rattarasan C (2006) Physiological and pathophysiological regulation of regional adipose tissue in the development of insulin resistance and type 2 diabetes. Acta Physiol 186:87–101

    Article  CAS  Google Scholar 

  14. Hu FB, Manson JE, Stampfer MJ et al (2001) Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345:790–797

    Article  PubMed  CAS  Google Scholar 

  15. Mokdad AH, Ford ES, Bowman BA et al (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289:76–79

    Article  PubMed  Google Scholar 

  16. Willet WC, Dietz WH, Colditz GA (1999) Guidelines for healthy weight. N Engl J Med 141:427–434

    Article  Google Scholar 

  17. Prospective Diabetes Study UK (1998) Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risks of complications in patients with type 2 diabetes (UKPPS 33). Lancet 352:837–853

    Google Scholar 

  18. Anon (2002) The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981–2997

    Google Scholar 

  19. Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Diabetes Prevention Program Reserved Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403

    Article  PubMed  CAS  Google Scholar 

  20. Padwal R, Li SK, Lau DCW (2004) Long-term pharmacotherapy for obesity and overweight (Cochrane Review). The Cochrane Library 3:C0004094

    Google Scholar 

  21. Norris SL, Zhang X, Avenell A et al (2004) Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 164:1395–1404

    Article  PubMed  CAS  Google Scholar 

  22. Chiasson JL, Josse RG, Gomes R et al (2003) STOP-NIDDM Trial Research Group. AcarBóse treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486–494

    Article  PubMed  CAS  Google Scholar 

  23. UK Prospective Diabetes Study Group (1996) UK Prospective Diabetes Study (UKPDS) 17. A 9-year update of a randomized controlled trial on the effect of improved metabolic control on complications in non-insulin dependent diabetes mellitus. Ann Intern Med 124:132–145

    Google Scholar 

  24. Chalmers J, Cooper ME (2008) UKPDS and the legacy effect. N Engl J Med 359:1618–1620

    Article  PubMed  CAS  Google Scholar 

  25. Holman RR, Paul SK, Bethel MA et al (2008) 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589

    Article  PubMed  CAS  Google Scholar 

  26. Pedersen O, Gaede P (2003) Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes. The Steno-2 study. Metabolism 52 [Suppl 1]:19–23

    Article  PubMed  CAS  Google Scholar 

  27. Haller H (1977) Epidemiology and associated risk factors of hyperlipoproteinemia. Z Gesamte Inn Med 32:124–128

    PubMed  CAS  Google Scholar 

  28. Phillips GB (1978) Sex hormones, risk factors and cardiovascular disease. Am J Med 65:7–11

    Article  PubMed  CAS  Google Scholar 

  29. Phillips GB (1977) Relationship between serum sex hormones and glucose, insulin, and lipid abnormalities in men with myocardial infarction. Proc Natl Acad Sci USA 74:1729–1733

    Article  PubMed  CAS  Google Scholar 

  30. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607

    Article  PubMed  CAS  Google Scholar 

  31. Kaplan NM(1989) The deadly quartet. Upper body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 149:1514–1520

    Article  PubMed  CAS  Google Scholar 

  32. De Fronzo RA, Ferranini E (1991) Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14:173–194

    Article  Google Scholar 

  33. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. I: Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabetes Med 15:539–553

    Article  CAS  Google Scholar 

  34. Hills SA, Backau B, Coppads SW et al (2004) The EGIR-RISC study (the European Group for the study of Insulin Resistance: relationship between insulin sensitivity and cardiovascular disease risk). I: Methodology and objectives. Diabetologia 47:566–570

    Article  CAS  Google Scholar 

  35. National Cholesterol Education Program (2002) Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 106:3143–3421

    Google Scholar 

  36. Eihorn D, Reaven GM, Cobin RH et al (2003) American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9:237–252

    Google Scholar 

  37. Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA 287:356–359

    Article  PubMed  Google Scholar 

  38. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE (1997) Risk variable clustering in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes 46:1594–1600

    Article  PubMed  CAS  Google Scholar 

  39. National Institute of Health Consensus Development Panel (1991) Gastrointestinal surgery for severe obesity. Ann Intern Med 115:956–961

    Google Scholar 

  40. Flint JM (1912) The effect of extensive resections of the small intestine. Bull Johns Hopkins Hosp 255:127

    Google Scholar 

  41. Weckesser EC, Clinn AB, Scott MW jr, Price JW (1949) Extensive resection of the small intestine. Am J Surg 78:706

    Article  PubMed  CAS  Google Scholar 

  42. Cattell RB (1945) Massive resection of the small intestine. Lahey Clin Bull 4:167

    PubMed  CAS  Google Scholar 

  43. Thoroughman JC, Walker LG jr, Raft D (1964) A review of 504 patients with peptic ulcer treated by hemigastrectomy and vagotomy. Surg Gynecol Obstet 119:257

    PubMed  CAS  Google Scholar 

  44. Price WE, Grizzle JE, Postlethwait RW, Johnson WD, Grabichi P (1970) Results of operation for duodenal ulcer. Surg Gynecol Obstet 131:233

    PubMed  CAS  Google Scholar 

  45. Friedman NM, Sancetta AJ, Magovern GJ (1955) The amelioration of diabetes mellitus following subtotal gastrectomy. Surg Gynecol Obstet 100:201–204

    PubMed  CAS  Google Scholar 

  46. Bittner R, Bittner B, Beger HG (1981) Homeostasis of glucose and gastric resection: the influence of food passage through the duodenum. Z Gastroenterology 19:698–707

    CAS  Google Scholar 

  47. Sjöström CD, Lissner L, Wedel H, Sjöström L (1999) Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS interventional study. Obes Res 7:477–484

    PubMed  Google Scholar 

  48. Cummings DE, Overduin J, Foster-Schubert KE (2003) Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 89:2608–2615

    Article  CAS  Google Scholar 

  49. Cummings DE, Shannon MH (2003) Ghrelin and gastric bypass. Is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab 88:2999–3002

    Article  PubMed  CAS  Google Scholar 

  50. Chen J, Muntner P, Hamm LH et al (2004) The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140:167–174

    PubMed  Google Scholar 

  51. Vinik AI, Erbas T, Park TS et al (2001) Dermal neurovascular dysfunction in type 2 diabetes. Diabetes Care 24:1468–1475

    Article  PubMed  CAS  Google Scholar 

  52. Haffner S, Taegtmeyer H (2003) Epidemic obesity and the metabolic syndrome. Circulation 108:1541–1545

    Article  PubMed  Google Scholar 

  53. Richardson DW, Vinik AI (2005) Metabolic implications of obesity: before and after gastric bypass. Gastroenterol Clin N Am 34:9–24

    Article  Google Scholar 

  54. Dixon JB, Bhathal PS, O'Brien PE (2001) Non-alcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91–100

    Article  PubMed  CAS  Google Scholar 

  55. Saltiel AR, Kahn CR (2001) Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414: 799–806

    Article  PubMed  CAS  Google Scholar 

  56. Almind K, Bjorback C, Vestergaard H et al (1993) Amino acid polymorphisms of insulin receptor substrate-1 in non insulin dependent diabetes mellitus. Lancet 342:828–832

    Article  PubMed  CAS  Google Scholar 

  57. North KE, Williams K, Williams JT et al (2003) Evidence for genetic factors underlying the insulin resistance syndrome in American Indians. Obes Res 11:1444–1448

    Article  PubMed  Google Scholar 

  58. Moller N, Gormsen L, Fugisan J et al(2003) Effects of aging on insulin secretion and action. Horm Res 60 [Suppl 1]:102–104

    PubMed  CAS  Google Scholar 

  59. Morino K, Petersen KF, Shulman GI (2006) Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55 [Suppl 2]:S9-S15

    Article  PubMed  CAS  Google Scholar 

  60. Machann J, Haring H, Schick F et al (2004) Intramyocellular lipis and insulin resistance. Diabetes Obes Metab 6:239–248

    Article  PubMed  CAS  Google Scholar 

  61. Kim JK, Gimeno RE, Higashimori T et al (2004) Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle. J Clin Invest 113:756–763

    PubMed  CAS  Google Scholar 

  62. Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115:1111–1119

    PubMed  CAS  Google Scholar 

  63. Yamada T, Katagirl H, Ishigaki Y et al (2006) Signals from intraabdominal fat modulate insulin and leptin sensitivity through different mechanisms: neuronal involvement in food-intake regulation. Cell Metab 3:223–229

    Article  PubMed  CAS  Google Scholar 

  64. Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MN, Berg AH et al (2002) Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 51:2591–2598

    Google Scholar 

  65. Hanley AJ, Bowden D, Wagenknecht LE, Balasubramanyam A, Langfeld C, Saad MF et al (2007) Associations of adiponectin with body fat distribution and insulin sensitivity in non-diabetic Hispanics and African-Americans. J Clin Endocrinol Metab 92:2665–2671

    Article  PubMed  CAS  Google Scholar 

  66. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe LC (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784–1792

    Article  PubMed  CAS  Google Scholar 

  67. Furler SM, Gan SK, Poynter AM et al (2006) Relationship of adiponectin with insulin sensitivity in humans, independent of lipid availability. Obesity 14:228–234

    Article  PubMed  CAS  Google Scholar 

  68. Hopkins TA, Ouchi N, Shibata R, Walsh K A(2007) diponectin actions in the cardiovascular system. Cardiovasc Res 74:11–18

    Article  PubMed  CAS  Google Scholar 

  69. McTernan CL, Mcternan PG, Harte AL, Levick PL, Barnett AH, Kumar S (2002) Resistin, antral obesity, and type 2 diabetes. Lancet 359:46–47

    Article  PubMed  CAS  Google Scholar 

  70. McTernan PG, Mcternan CL, Chetty R, Jenner K, Fisher FM, Laner MN et al (2002) Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 87:2407

    Article  PubMed  CAS  Google Scholar 

  71. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K et al (2002) A central role for JNK in obesity and insulin resistance. Nature 420:333–336

    Article  PubMed  CAS  Google Scholar 

  72. Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB et al (2001) Regulation of resistin expression in circulating levels in obesity, diabetes, and fasting. Diabetes 50:2199–2202

    Article  Google Scholar 

  73. Rasouli N, Kern PA (2008) Adipocytokines and the Metabolic Complications of Obesity. J Clin Endocrinol Metab 93:S64–S73

    Article  PubMed  CAS  Google Scholar 

  74. Hivert M, Sullivan LM, Fox CS et al (2008) Associations of adiponectin, resistin, and tumor necrosis factor-α with insulin resistance. J Clin Endocrinol Metab 93:3165–3172

    Article  PubMed  CAS  Google Scholar 

  75. Milan G, Granzotto M, Scanda A, Calcagno A, Paguno C, Federspil G et al (2002) Regional adipose tissue differences of resistin and adiponectin expression in genetically obese rats: effects of weight loss. Obes Res 10:1095–1103

    Article  PubMed  CAS  Google Scholar 

  76. Silswal N, Singh AK, Aruna B, Mukhopadyay S, Ghosh S, Ehtensham NZ (2005) Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappa B dependent pathway. Biochem Biochys Res Commun 334:1092–1101

    Article  CAS  Google Scholar 

  77. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth hormone-releasing acylated peptide from stomach. Nature 402:656–660

    Article  PubMed  CAS  Google Scholar 

  78. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T et al (2000) Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255–4261

    Article  PubMed  CAS  Google Scholar 

  79. Cummings DE, Shannon MH(2003) Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 138:389–396

    Article  PubMed  CAS  Google Scholar 

  80. Cummings DE, Purnel JQ, Frayo RS et al (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiaiton in humans. Diabetes 50:1714–1719.

    Article  PubMed  CAS  Google Scholar 

  81. Aylin S (2005) Gastrointestinal surgery and gut hormones. Curr Opin Endocrinol Diabetes 12:89–98

    Article  Google Scholar 

  82. Kreyman B, Williams G, Ghatei MA, Bloom SR (1987) Glucagonlike peptide-1 (7–36): a physiological incretin in man. Lancet 2:1300–1304

    Article  Google Scholar 

  83. Bloom SR, Polak JM (1980) Gut hormones. Adv Clin Chem 21:177–244

    Article  PubMed  CAS  Google Scholar 

  84. Perley MJ, Kipnis DM (1967) Plasma insulin responses to oral and intravenous glucose studies in normal and diabetic subjects. J Clin Invest 46:1954–1962

    Article  PubMed  CAS  Google Scholar 

  85. Preitner F, Iberson M, Franklin I et al (2004) Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 113:635–645

    PubMed  CAS  Google Scholar 

  86. Drucker DJ (2002) Biological actions therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531–544

    Article  PubMed  CAS  Google Scholar 

  87. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25:781–792

    Article  PubMed  CAS  Google Scholar 

  88. Gutzwiller JP, Drewe J, Goke B, Schmidt H et al (1999) Glucagonlike peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 276:R1541–R1544

    PubMed  CAS  Google Scholar 

  89. Nauck M, Stockman F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46–52

    Article  PubMed  CAS  Google Scholar 

  90. Nauck MA, Heimesaat MM, Orksov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like (7–36 amide) but not of synthetic human gastrin inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 91:301–307

    Article  PubMed  CAS  Google Scholar 

  91. Elahi D, McAloon-Dyke M, Fukagawa NK et al (1994) The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-2 (7–37) in normal and diabetic subjects. Regul Pept 51:63–74

    Article  PubMed  CAS  Google Scholar 

  92. Batterham RL, Cohen MA, Small CJ et al (2002) Gut hormone PYY 3–36 physiologically inhibits food intake. Nature 418:650–654

    Article  PubMed  CAS  Google Scholar 

  93. Batterham RL, Cohen MA, Ellis SM et al (2003) Inhibition of food intake in obese subjects by peptide YY 3–36. N Engl J Med 349:941–948

    Article  PubMed  CAS  Google Scholar 

  94. Stok S, Leichner P, Wong ACK et al (2005) Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab 90:2161–2168

    Article  CAS  Google Scholar 

  95. Le Roux CW, Batterham RL, Aylwin SJ et al (2006) Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147:3–8

    Article  PubMed  CAS  Google Scholar 

  96. Hickey MS, Pories WJ, MacDonald KG et al (1998) A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg 227:637–644

    Article  PubMed  CAS  Google Scholar 

  97. Schauer PR, Burguera B, Ikramuddin S et al (1995) Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann Surg 222:339–352

    Article  Google Scholar 

  98. Sjöström L, Lindroos AK, Peltonen M et al (2004) Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 years after Bariatric Surgery: The Swedish Obese Subjects Study Scientific Group for Swedish Obese Surbjects Trial. N Engl J Med 351:2683–2693

    Article  PubMed  Google Scholar 

  99. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K et al (2004) Bariatric surgery: a systematic review and meta-analysis. JAMA 292:1724–1737

    Article  PubMed  CAS  Google Scholar 

  100. Nguyen NT, Goldman C, Rosenquist CJ et al (2001) Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg 234:279–289

    Article  PubMed  CAS  Google Scholar 

  101. Scopinaro N, Adami GF, Marinari GM et al (1998) Biliopancreatic diversion. World J Surg 22:936–946

    Article  PubMed  CAS  Google Scholar 

  102. Schauer PR, Ikramuddin S, Gourash W et al (2000) Outcomes after laparoscopic roux-en-Y gastric bypass for morbid obesity. Ann Surg 232:515–529

    Article  PubMed  CAS  Google Scholar 

  103. Schauer PR, Burguera B, Ikramudin S, Cottam D et al (2003) Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 238:467–485

    PubMed  Google Scholar 

  104. Holdstock C, Engstrom BE, Obrvall M et al (2003) Ghrelin and adipose tissue regulatory peptides: effects of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 88:3177–3183

    Article  PubMed  CAS  Google Scholar 

  105. Geloneze B, Tambascia MA, Pilla VF et al (2003) Ghrelin: a gutbrain hormone: effect of gastric bypass surgery. Obes Surg 13:17–22

    Article  PubMed  Google Scholar 

  106. Rubino, F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J et al (2004) The Early Effects of the Roux-en-Y Gastric Bypass on hormones involved in body weight regulation on glucose metabolism. Ann Surg 240:236–242

    Article  PubMed  Google Scholar 

  107. Strader AD, Torsten PV, Jandacek RJ, Woods SC, Alessio DA, Seeley RJ (2005) Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol Endocrinol Metab 288:E447–E453

    Article  PubMed  CAS  Google Scholar 

  108. Pacheco D, De Luis DA, Romero A, González Sagrado M et al (2007) The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg 194:221–224

    Article  PubMed  CAS  Google Scholar 

  109. Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK (2008) Weight loss, appetite suppression, and changes in fasting and post-prandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy. A prospective, double blind study. Ann Surg 247:401–407

    Article  PubMed  Google Scholar 

  110. Patriti A, Aisa MC, Annetti C, Sidoni A et al (2007) How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced proglucagon gene expression and L-cell number. Surgery 142:74–85

    Article  PubMed  Google Scholar 

  111. Ie Roux CW, Aylwin SJ, Batterham RL et al (2006) Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 243:108–114

    Article  PubMed  Google Scholar 

  112. Buettner C, Muse ED, Cheng A et al (2008) Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med 14:667–675

    Article  PubMed  CAS  Google Scholar 

  113. Rubino F, Zizzari P, Tomassetto C et al (2005) The role of the small bowel in the regulation of circulating ghrelin levels and food intake in the obese Zucker rat. Endocrinology 146:1745–1751

    Article  PubMed  CAS  Google Scholar 

  114. Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G et al (2006) The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 244:741–749

    Article  PubMed  Google Scholar 

  115. Rubino F, Marescaux J (2004) Effects of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes. A new perspective for an old disease. Ann Surg 239:1–11

    Article  PubMed  Google Scholar 

  116. Mason EE (1999) Ileal transposition and enteroglucagon/GLP-1 in obesity and diabetic surgery. Obes Surg 9:223–228

    Article  PubMed  CAS  Google Scholar 

  117. Mason EE (2005) The mechanism of surgical treatment of type 2 diabetes. Obes Surg 15:459–461

    Article  PubMed  Google Scholar 

  118. Dixon JB, O'Brien PE, Playfair J et al (2008) Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299:316–323

    Article  PubMed  CAS  Google Scholar 

  119. Bourdages H, Goldenberg F, Nguyen P et al (1994) Improvement in obesity-associated medical conditions following vertical banded gastroplasty and gastrointestinal bypass. Obes Surg 4:227–231

    Article  PubMed  Google Scholar 

  120. Kellum JM, Kuemmerle JF, O'Dorisio RM et al (1990) GI hormone response to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 211:763–771

    Article  PubMed  CAS  Google Scholar 

  121. Scopinaro N, Gianetta E, Civalleri D et al (1979) Bilio-pancreatic bypass for obesity. II: Initial experience in a man. Br J Surg 66:618–620

    Article  PubMed  CAS  Google Scholar 

  122. Scopinaro N, Marinari GM, Camerini GB et al (2005) Specific effects of biliopancreatic diversión on the major components of metabolic síndrome: a long-term follow-up study. Diabetes Care 28:2406–2411

    Article  PubMed  Google Scholar 

  123. Scopinaro N, Papadia F, Marinari G, Camerini G, Adami G (2007) Long-term control of type 2 diabetes mellitus and the other major components of the metabolic syndrome after biliopancreatic diversion in patients with BMI <35 kg/m2. Obes Surg 17:193–194

    Article  Google Scholar 

  124. Hess DS, Hess DW (1998) Biliopancreatic diversion with a duodenal switch. Obes Surg 8:267–282

    Article  PubMed  CAS  Google Scholar 

  125. Marceau P, Hould FS, Simard S et al (1998) Biliopancreatic diversion with duodenal switch. World J Surg 22:947–954

    Article  PubMed  CAS  Google Scholar 

  126. Marceau P, Biron S, Hould FS, Lebel S, Marceau S, Lescelleur O et al (2008) Duodenal switch improved standard biliopancreatic diversion: a retrospective study. Surg Obes Relat Dis 5:43–7

    Article  PubMed  Google Scholar 

  127. Marceau P, Biron S, Hould FS, Lebel S, Marceau S, Lescelleur O et al (2007) Duodenal switch: long-term results. Obes Surg 17:1421–1430

    Article  PubMed  Google Scholar 

  128. Mason EE, Ito C (1967) Gastric bypass in obesity. Surg Clin North Am 47:1345–1351

    PubMed  CAS  Google Scholar 

  129. Vidal J, Ibarzabal A, Romero F, Delgado S, Momblán D, Flores L et al (2008) Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg 18:1077–1082

    Article  PubMed  CAS  Google Scholar 

  130. Gagner M, Gumbs AA, Milone L, Yung E, Goldenberg L, Pomp A (2008) Laparoscopic sleeve gastrectomy for the super-superobese (body mass index >60 kg/m2). Surg Today 38:399–403

    Article  PubMed  Google Scholar 

  131. Milone L, Strong V, Gagner M (2005) Laparoscopic sleeve gastrectomy is superior to endoscopic intragastric balloon as a first stage procedure for super-obese patients (BMI > or =50). Obes Surg 15:612–617

    Article  PubMed  Google Scholar 

  132. Silecchia G, Boru C, Pecchia A, Rizzello M, Casella G, Leonetti F et al (2006) Effectiveness of laparoscopic sleeve gastrectomy (first stage of biliopancreatic diversion with duodenal switch) on co-morbidities in super-obese high-risk patients. Obes Surg 16:1138–1144

    Article  PubMed  Google Scholar 

  133. Regan JP, Inabnet WB, Gagner M, Pomp A (2003) Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient. Obes Surg 13:861–864

    Article  PubMed  CAS  Google Scholar 

  134. DePaula AL et al (2008) Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc 22:706–716

    Article  PubMed  CAS  Google Scholar 

  135. Ferzli GS, Dominique E, Ciaglia M (2009) Clinical evaluation of the effect of the duodenal-jejunal bypass on type 2 diabetes. World J Surg 33:972–979

    Article  PubMed  CAS  Google Scholar 

  136. Cohen R (2008) Duodenojejunal bypass for the treatment of type 2 diabetes mellitus in patients with BMI from 22 to 34. Presented at the first United States Metabolic Surgery Summit; Miami Beach, Florida; January 12

    Google Scholar 

Download references

Authors
  1. Joel Ricci MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Timoney MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George Ferzli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abt. Allgemein- und Viszeralchirurgie, Universitätsklinikum Freiburg, Hugstetter Str. 55, 79106, Freiburg

    W. Konrad Karcz  & Oliver Thomusch  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ricci, J., Timoney, M., Ferzli, G. (2012). Innovative Approach to Treatment of the Metabolic Syndrome. In: Karcz, W.K., Thomusch, O. (eds) Principles of Metabolic Surgery. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-02411-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-02411-5_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-02410-8

  • Online ISBN: 978-3-642-02411-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation